This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Clinical and Laboratory Evaluation

Wally S. Buch, MD; Robert D. Pipkin, MD; Warren D. Hancock, MBA; Thomas J. Fogarty, MD

Arch Surg. 1975;110(11):1408-1415.

Abstract
• From March 1971 through April 1975, one hundred twenty patients underwent mitral valve replacement with a Hancock "stabilized glutaraldehyde process" porcine aortic xenograft. A simultaneous canine experimental series was also carried out. In the clinical series, the early mortality was 8.3%. Actuarial analyses of all patients predicts survival at two years of 81.0% and at four years of 70.0%. The predicted survival for patients without coronary artery disease or prior prosthetic valve replacement is 87.5% at two years and 77.5% at four years. There were four thromboembolic episodes, a rate of 2.4% per patient-year. None were fatal. No valve failures were noted. Histologic examination and shrink temperature analysis of recovered valves show excellent tissue preservation at 40 months. The data indicate that the Hancock valve is durable, enjoys a low incidence of thromboembolism, and may be the valve of choice for mitral valve replacement.

(Arch Surg 110:1408-1415, 1975)

Author Affiliations
From the Stanford (Calif) University Hospital.

Footnotes
Accepted for publication June 27, 1975.

Read before the 23rd scientific meeting of the International Cardiovascular Society, Boston, June 20, 1975.

Reprint requests to 770 Welch Rd, Suite 201, Palo Alto, CA 94304 (Dr Fogarty).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?